What is the equity of Inhibrx this year?
Inhibrx has equity of 43.5 M USD this year.
Inhibrx Equity 2024
Inhibrx Equity
43.5 M USD
Ticker
INBX
ISIN
US45720L1070
WKN
A2PQMH
In 2024, Inhibrx's equity was 43.5 M USD, a -25.12% increase from the 58.1 M USD equity in the previous year.
Inhibrx Aktienanalyse
What does Inhibrx do?
Inhibrx Inc is a biopharmaceutical company specializing in the development and commercialization of therapeutic antibodies. The company was founded in 2011 and is headquartered in La Jolla, California. Inhibrx's business model is based on the research and development of innovative antibodies targeting various diseases such as cancer, inflammation, autoimmune diseases, and infectious diseases. The company utilizes proprietary technologies and platforms to produce a wide range of antibodies that specifically target and block key proteins in the body. Inhibrx is divided into two business segments: the clinical development department and the research and development department. The clinical development department is responsible for conducting clinical trials of the company's antibodies. The research and development department is responsible for the development and refinement of new antibody platforms and technologies. Inhibrx has a number of products in the pipeline, including IRX-2, an antibody developed for the treatment of patients with solid tumor diseases. IRX-2 targets the PD-L1 and PD-L2 proteins, which are overexpressed by many cancer cells and help tumor cells evade immune defenses. In clinical studies, IRX-2 has shown significant reduction in tumor volume in many patients. Another promising product from Inhibrx is IRX-6, an antibody developed for the treatment of autoimmune diseases such as lupus and rheumatoid arthritis. IRX-6 targets the protein BAFF, which plays a key role in the activation of immune cells. Inhibrx has also partnered with pharmaceutical company Celgene Corporation to develop new cancer therapies. As part of the partnership, Inhibrx will utilize its proprietary antibody platforms and technologies to identify and develop new cancer therapies. Inhibrx has an excellent reputation in the industry and has been recognized multiple times for its innovative approaches and technologies. The company has secured a place among the leading biopharmaceutical companies and is expected to continue playing a significant role in the development of new therapies. Inhibrx ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Inhibrx's Equity
Inhibrx's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Inhibrx's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Inhibrx's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Inhibrx's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Inhibrx’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Inhibrx stock
What was the equity of Inhibrx compared to the previous year?
The equity of Inhibrx has increased/decreased by -25.12% decreased compared to the previous year.
What impact does a high equity have on investors of Inhibrx?
A high equity is advantageous for investors of Inhibrx as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Inhibrx?
A low equity can be a risk for investors of Inhibrx, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Inhibrx affect the company?
An increase in equity of Inhibrx can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Inhibrx affect the company?
A reduction in equity of Inhibrx can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Inhibrx?
Some factors that can affect the equity of Inhibrx include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Inhibrx so important for investors?
The equity of Inhibrx is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Inhibrx take to change the equity?
To change equity, Inhibrx can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Inhibrx pay?
Over the past 12 months, Inhibrx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inhibrx is expected to pay a dividend of 0 USD.
What is the dividend yield of Inhibrx?
The current dividend yield of Inhibrx is .
When does Inhibrx pay dividends?
Inhibrx pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Inhibrx?
Inhibrx paid dividends every year for the past 0 years.
What is the dividend of Inhibrx?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Inhibrx located?
Inhibrx is assigned to the 'Health' sector.
Wann musste ich die Aktien von Inhibrx kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Inhibrx from 10/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/8/2024.
When did Inhibrx pay the last dividend?
The last dividend was paid out on 10/8/2024.
What was the dividend of Inhibrx in the year 2023?
In the year 2023, Inhibrx distributed 0 USD as dividends.
In which currency does Inhibrx pay out the dividend?
The dividends of Inhibrx are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Inhibrx
Our stock analysis for Inhibrx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inhibrx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
